ArticleJournal of pharmacy & bioallied sciences
Comparative Efficacy and Safety of SSRIs and TCAs in the Management of Major Depressive Disorder: A Prospective Observational Study.
Article in Journal of pharmacy & bioallied sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psychiatric disorders form an important public health priority and major causes of morbidity. Major Depressive Disorder (MDD) is a severe psychiatric illness characterized by persistent sadness, loss of interest, lack of energy, disturbed sleep, and suicidality with lifetime prevalence rate for MDD is 16.2%. Treatment options for depression include medication, primarily antidepressants, psychotherapy which includes cognitive-behavioral therapy (CBT), interpersonal therapy (IPT), and electroconvulsive therapy. Method: A prospective observational study was conducted in psychiatric department of VIMSAR, Burla taking 50 patients diagnosed with MDD for a period of 24 months. Efficacy and safety between Selective Serotonin Reuptake Inhibitors (SSRIs) and Tricyclic Antidepressants (TCAs) were evaluated using Clinical Global Impression-Severity (CGI-S) scale, Clinical Global Impression-Improvement (CGI-I) scale, and Montgomery-Asberg Depression Rating Scale (MADRS) scores. Results: Dosulepin/Dothiepin (TCA) was most frequently prescribed antidepressant followed by escitalopram (SSRI). The efficacy of SSRIs is equivalent to that of TCAs. There was no significant difference among the antidepressants about reductions in the total scores on CGI-S, CGI-I and MADRS scales. Dry mouth and weight gain were the most frequently reported adverse drug reactions (ADRs). Conclusion: Antidepressants used for therapy of MDD in our study were effective in clinical improvement, better compliance on long term basis except for side effect profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.